Purchase this article with an account.
Yoshihiro Takamura, Takeshi Tomomatsu, Takehiro Matsumura, Yuji Takihara, Masanori Sakashita, Shogo Arimura, Makoto Gozawa, Satoshi Yokota, Masaru Inatani; Vitreous and aqueous concentrations of topically applied brimonidine tartrate 0.1%. Invest. Ophthalmol. Vis. Sci. 2015;56(7 ):5747.
Download citation file:
© ARVO (1962-2015); The Authors (2016-present)
To determine the vitreous and aqueous concentrations of brimonidine after topical application of the ophthalmic solution 0.1%.
The prospective observational case series included patients with an idiopathic epiretinal membrane or macular hole who were scheduled for a pars plana vitrectomy. Brimonidine tartrate ophthalmic solution 0.1% was topically administered twice daily for 1 week preoperatively. Vitreous and aqueous humor were collected before vitrectomy, then, the brimonidine concentration was measured with liquid chromatography tandem spectrometry (LC/MS/MS).
Twenty-four patients (19 phakic eyes and 5 pseudophakic eyes) were enrolled. The mean concentrations in the aqueous humor and vitreous were 336.0 ± 276.2 nM and 4.8 ± 3.2 nM, respectively. A significant relationship was observed between the vitreous and aqueous samples (P = 0.034, R2 = 0.22). Nineteen (79%) of the 24 eyes showed the more than 2 nM of brimonidine tartate concentration in the vitreous. In the phakic eyes, the mean concentration of brimonidine in the vitreous was 4.9 ± 3.3 nM while the mean concentration in the pseudophakic eyes was 4.1 ± 2.4 nM, demonstrating no significant difference between pseudophakic and phakic eyes (P = 0.59).
After one week of dosing, most of the patients who topically received brimonidine tartrate 0.1%, the concentration in the vitreous of the molecule above 2 nM, which is known to activate neuroprotective a-2 receptors in animal retina. The drug penetration into the vitreous seems to be independent of lens status.
This PDF is available to Subscribers Only